Per the US Prescribing Information, the recommended starting dosage is 2.5 mg injected subcutaneously once weekly. The 2.5 mg dosage is for treatment initiation and is not intended for glycemic control. Confirm details on the current FDA label and with your clinician.

Last updated September 25, 2026 · Educational / label paraphrase

Mounjaro® titration schedule: what the US label says

Not affiliated with Eli Lilly. Mounjaro®, Zepbound®, and KwikPen® are trademarks of Eli Lilly and Company (or its affiliates). This page is independent educational content—not medical advice.

Escalation in 2.5 mg steps after at least 4 weeks on the current dose is a core theme of the US Prescribing Information for Mounjaro (tirzepatide). Adults have a labeled maximum of 15 mg once weekly; pediatric maxima differ—always read the live label. Your clinician decides whether, when, and how far to escalate.

Boxed warning: Tirzepatide products carry a boxed warning about thyroid C-cell tumors in rodents; human relevance for MTC is unknown. Contraindications related to personal/family history of MTC or MEN2 appear on the label. Review the official FDA / DailyMed documents and side-effects overview with your clinician.

Educational overview of labeled steps

The following table paraphrases common US-label themes for adults. It is not a prescription and is not a “you should start at X” instruction. Verify against the current Prescribing Information and your clinician’s plan.

Theme (US label paraphrase)	Educational note
Starting dosage	2.5 mg subcutaneously once weekly for treatment initiation; not intended for glycemic control per label language.
Escalation increment	Increase in 2.5 mg increments after at least 4 weeks on the current dose, as clinically appropriate.
Maintenance / higher doses	Subsequent labeled strengths commonly discussed include 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg once weekly—confirm on the live label for your presentation.
Adult maximum	Maximum recommended dosage 15 mg once weekly (adults). Pediatric dosing differs—see official labeling.
Administration	Once weekly; injection technique belongs in the official Instructions for Use—not on this website (we do not publish injection HowTo schema).

Sources: Paraphrase themes from the Mounjaro US Prescribing Information / Medication Guide via FDA Drug Labeling and DailyMed. Label citations checked as of September 25, 2026—verify the current documents before relying on any detail.

What titration does not mean

It does not guarantee fewer side effects for every person.
It does not authorize self-directed dose changes from a website or forum.
It does not apply unchanged to compounded tirzepatide (which is not FDA-approved Mounjaro®).
It does not replace reading the IFU for your specific pen, KwikPen®, or vial presentation.

FAQ

Why start at 2.5 mg?

Per the US label, 2.5 mg once weekly is the recommended starting dosage for initiation and is not intended for glycemic control. Confirm with your clinician and the current FDA label.

How long between dose increases?

The label describes increasing in 2.5 mg increments after at least 4 weeks on the current dose. Escalation is a clinical decision.

What is the adult maximum weekly dose on the label?

15 mg once weekly for adults per US label themes. Pediatric maxima differ—see the official label.

Does titration guarantee fewer side effects?

No. Gradual escalation may help gastrointestinal tolerability for many people, but results vary. Report concerning symptoms to your clinician.